Abstract
Introduction

Cardiovascular disease remains the leading cause for morbidity/ mortality in the Western world. Cell transplantation into the damaged myocardium (cell therapy) has received extensive attention as a regenerative tool, and the accumulated evidence from both pre-clinical and clinical studies suggests that it has the potential to restore heart function. Currently, cellular cardiomyoplasty is being actively explored as therapy for regenerating the damaged myocardium, using different cell types, mostly derived from bone marrow or skeletal muscle. The clinical trials have highlighted the need to improve survival, engraftment and differentiation of the transplanted cells. Clearly a number of issues remain including the number of cells, the choice of an appropriate cell source that is able to provide all the main cell types of the heart and also the poor retention of the transplanted cells. In this review we will focus on cardiac tissue engineering (CTE), with particular attention to the improvements that this methodology can offer compared to conventional cell injection therapy.
Lessons from cell therapy
During the last few years, cellular therapy for the diseased heart has shown encouraging results on cardiac function in animal models of heart ischemia, using a variety of different cells, even without clear cardiovascular differentiation of the transplanted cells [1] . Several years after the first human clinical applications using non-cardiac stem cells as a therapy for acute myocardial infarction, heart failure or refractory angina, it should be recognized that the results are mixed, with benefits ranging from absent to transient, but marginal at most [1] .
Pre-clinical studies demonstrated promising results and also short-term effects in patients were observed; however, in most trials long-term follow-up has shown that conventional pharmacological therapy often has the same late outcome as cellular therapy [1] . Cell [8, 9] .
When cells are injected into an arrested heart by thiopental injection, cell retention is four times higher than injection into a beating heart. This indicates that cardiac contraction and/or myocardial perfusion are important in the early washout of cells [10] . In addition, an increase in cell retention is obtained by fibrin glue application on the site of injection [10] . Survival and retention can also be improved when cells are transplanted together with a matrix such as liquid collagen [11] or fibrin glue [12] [16] . [17] . [19] . This cardiac ECM is a viscous liquid solution up to room temperature, and will become a gel at 37ЊC [19] . Preliminary studies demonstrated that the gel, when placed in a clinically compatible catheter, can be pushed through with minimal resistance, indicating the clinical applicability of the materials [19] . [26] , and cultivated them in a preformed commercially available collagen scaffold or in gelatine-based scaffolds [27, 28] .
The application of alginate as a gel directly injected into the heart has been also reported. When alginate was injected directly in the myocardial wall of a 7-day-old MI, the alginate matrix significantly increased scar thickness, systolic and diastolic wall thickening, and cardiac function as compared to saline or cardiomyocyte injection alone. Similar beneficial effects in scar thickness and remodelling were obtained also when alginate was injected in a 2-month-old infarct
Hao et al. used a VEGF-A or PDGF-BB modified alginate scaffold and injected this into a MI model [18]. The controlled release of the growth factors (alone or in combination) from the matrix was confirmed experimentally in vitro. Although the addition of growth factors induced vessel formation and increased smooth muscle cell infiltration, no differences in left ventricle diastolic diameter and ejection fraction could be observed [18]. Another intriguing approach is the use of a-cellular matrix as a gel that can be injected into the heart. Singelyn et al. recently reported the isolation of ECM from pig ventricle as a gel
In vitro CTE applications
CPCs grown as cardiospheres represent per se a real cardiac microtissue, in which the more differentiated cells are located in the external layers whereas those proliferating and expressing stemness and angiogenic markers are in the core.
Moreover our previous observations [26, 29, 30] (Fig. 1a) . Some differences in the spreading out and production of extracellular matrix were observed, with a more consistent proliferation in the commercial collagen scaffold.
CSps displayed very good integration with both matrices, as demonstrated by scanning electron microscope analysis (Fig. 1b) [1] .
Conclusions
